Targeting heparan sulfate proteoglycans in breast cancer treatment

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 3, 2008, Pages 151-158

  Koo, Chuay Yeng ^a   Sen, Yin Ping ^a   Bay, Boon Huat ^a   Yip, George W ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angiogenesis; Breast cancer; Endosulfatase; Glycosaminoglycans; Glypican; Heparan sulfate; Heparanase; Heparin; Metastasis; Phosphomannopentaose sulfate; Proteoglycans; Syndecan; Treatment

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CORE PROTEIN; DALTEPARIN; DOCETAXEL; ENOXAPARIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLYPICAN 1; GLYPICAN 3; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPASE C; PHOSPHOMANNOPENTAOSE SULFATE; PI 88; PLACEBO; PROTEOHEPARAN SULFATE; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1; SYNDECAN 4; TINZAPARIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER MORTALITY; CELL FUNCTION; CELL SURFACE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BINDING SITE; DRUG STRUCTURE; DRUG SULFATION; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; VENOUS THROMBOEMBOLISM;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS;

EID: 58049215512     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208786242278     Document Type: Review

References (93)

1. American Cancer Society. Cancer facts & figures 2008. Atlanta, American Cancer Society 2008.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
3. Breen N, Cronin A, Meissner HI, et al. Reported drop in mammography: is this cause for concern? Cancer 2007; 109: 2405-2409.
4. American Cancer Society. Breast cancer facts & figures 2007-2008. Atlanta, American Cancer Society 2008.
5. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008; 83: 26-36.
6. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008; 26: 798-805.
7. Conte P, Guarneri V, Bengala C. Evolving nonendocrine therapeutic options for metastatic breast cancer: How adjuvant chemotherapy influences treatment. Clin Breast Cancer 2007; 7: 841-849.
8. Thimmegowda NR, Swamy SN, Kumar CS, et al. Synthesis, characterization and evaluation of benzimidazole derivative and its precursors as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Bioorg Med Chem Lett 2008; 18: 432-435.
9. Kumar CS, Swamy SN, Thimmegowda NR, Prasad SB, Yip GW, Rangappa KS. Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Med Chem Res 2007; 16: 179-187.
10. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 2006; 5: 2139-2148.
11. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: Host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
12. Teng YH, Tan PH, Chia SJ, et al. Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod Pathol 2008; 21: 893-901.
13. Zou XH, Foong WC, Cao T, Bay BH, Ouyang HW, Yip GW. Chondroitin sulfate in palatal wound healing. J Dent Res 2004; 83: 880-885.
14. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
15. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001; 11: 75-82.
16. Kreuger J, Prydz K, Pettersson RF, Lindahl U, Salmivirta M. Characterization of fibroblast growth factor 1 binding heparan sulfate domain. Glycobiology 1999; 9: 723-729.
17. Sugaya N, Habuchi H, Nagai N, Ashikari-Hada S, Kimata K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 2008; 283: 10366-10376.
18. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-3163.
19. Guo CH, Koo CY, Bay BH, Tan PH, Yip GW. Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int J Oncol 2007; 31: 1415-1423.
20. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-3441.
21. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-2039.
22. Boyd DD, Nakajima M. Involvement of heparanase in tumor metastases: a new target in cancer therapy? J Natl Cancer Inst 2004; 96: 1194-1195.
23. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 2004; 23: 341-352.
24. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005; 24: 4037-4051.
25. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev 2004; 22: 1-6.
26. Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
27. Chow LQ, Gustafson DL, O'Bryant CL, et al. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol 2008 (in press).
28. Conrad HE. Heparin-binding proteins. San Diego, Academic Press 1998.
29. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of Glycobiology. New York, Cold Spring Harbor Laboratory Press 1999.
30. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-248.
31. Gulba DC. Anticoagulant drugs. Herz 1996; 21: 12-27.
32. Schafer AI, Levine MN, Konkle BA, Kearon C. Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program 2003; 520-539.
33. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-136.
34. Kakkar AK, Williamson RC. Thromboprophylaxis in the cancer patient. Haemostasis 1998; 28 Suppl 3: 61-65.
35. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476.
36. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
37. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824.
38. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
39. Seeholzer N, Thurlimann B, Koberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: Results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood Coagul Fibrinolysis 2007; 18: 415-423.
40. Bertolesi GE, Lauria de Cidre L, Eijan AM. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumour Biol 1994; 15: 275-283.
41. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003; 9: 553-566.
42. Marchetti M, Vignoli A, Russo L, et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 2008; 121: 637-645.
43. Vlodavsky I, Ilan N, Nadir Y, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007; 120 Suppl 2: S112-S120.
44. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids? Clin Cancer Res 2007; 13: 1562-1570.
45. Zimmermann P, David G. The syndecans, tuners of transmembrane signaling. FASEB J 1999; 13 Suppl: S91-S100.
46. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1-16.
47. Leppa S, Mali M, Miettinen HM, Jalkanen M. Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 1992; 89: 932-936.
48. Leppa S, Harkonen P, Jalkanen M. Steroid-induced epithelial-fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells. Cell Regul 1991; 2: 1-11.
49. Mali M, Jaakkola P, Arvilommi AM, Jalkanen M. Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans. J Biol Chem 1990; 265: 6884-6889.
50. Gotte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 2006; 26: 621-627.
51. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-483.
52. Matsuda K, Maruyama H, Guo F, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001; 61: 5562-5569.
53. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11-18.
54. Baba F, Swartz K, van BR, et al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat 2006; 98: 91-98.
55. Tsanou E, Ioachim E, Briasoulis E, et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J Exp Clin Cancer Res 2004; 23: 641-650.
56. Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999; 112: 377-383.
57. Maeda T, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006; 25: 1408-1412.
58. Mennerich D, Vogel A, Klaman I, et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 2004; 40: 1373-1382.
59. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 2004; 64: 612-621.
60. 3 integrin activity in human mammary carcinoma cells. J Cell Biol 2004; 167: 171-181.
61. 3 integrins in human breast carcinoma cells. Exp Cell Res 2003; 286: 219-232.
62. 3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007; 67: 5821-5830.
63. Sloan EK, Anderson RL. Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 2002; 59: 1491-1502.
64. Oh ES, Woods A, Lim ST, Theibert AW, Couchman JR. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. J Biol Chem 1998; 273: 10624-10629.
65. Oh ES, Woods A, Couchman JR. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem 1997; 272: 11805-11811.
66. Oh ES, Woods A, Couchman JR. Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 1997; 272: 8133-8136.
67. Wilcox-Adelman SA, Denhez F, Iwabuchi T, Saoncella S, Calautti E, Goetinck PF. Syndecan-4: Dispensable or indispensable? Glycoconj J 2002; 19: 305-313.
68. Chen RL, Lander AD. Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 2001; 276: 7507-7517.
69. Korc, M., Lander, A.D.: US20070026471A1 (2007).
70. David G, Lories V, Decock B, Marynen P, Cassiman JJ, Van Den BH. Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts. J Cell Biol 1990; 111: 3165-3176.
71. Sasisekharan H, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002; 2: 521-528.
72. Filmus J. Glypicans in growth control and cancer: Glycobiology 2001; 11: 19R-23R.
73. Bianco C, Strizzi L, Rehman A, et al. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003; 63: 1192-1197.
74. Saloman DS, Bianco C, Ebert AD, et al. The EGF-CFC family: Novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 2000; 7: 199-226.
75. Wechselberger C, Ebert AD, Bianco C, et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001; 266: 95-105.
76. Matossian-Rogers, A.: GB2429013 (2007).
77. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001; 20: 7408-7412.
78. Powell CA, Xu G, Filmus J, Busch S, Brody JS, Rothman PB. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest 2002; 121: 6S-7S.
79. Yan PS, Chen CM, Shi H, et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Rca 2001; 61: 8375-8380.
80. Peters MG, Farias E, Colombo L, Filmus J, Puricelli L, Bal de Kier JE. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 2003; 80: 221-232.
81. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006; 13: 2101-2111.
82. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006; 66: 10233-10237.
83. Li JP, Heparin, heparan sulfate and heparanase in cancer: Remedy for metastasis? Anticancer Agents Med Chem 2008; 8: 64-76.
84. Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 2004; 95: 553-558.
85. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002; 277: 49175-49185.
86. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003; 278: 23107-23117.
87. Narita K, Chien J, Mullany SA, et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 2007; 282: 14413-14420.
88. Narita K, Staub J, Chien J, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006; 66: 6025-6032.
89. Uchimura K, Morimoto-Tomita M, Bistrup A, et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: Effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006; 7:2.
90. Morimoto-Tomita M, Uchimura K, Bistrup A, et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005; 7: 1001-1010.
91. Koo CY, Bay BH, Lui PC, Tse GM, Tan PH, Yip GW. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors. Mod Pathol 2006; 19: 1344-1350.
92. Safaiyan F, Lindahl U, Salmivirta M. Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem 1998; 252: 576-582.
93. Gengrinovitch, S.: US20070160573A1 (2007).